Navigation Links
Intensive therapy halves kidney disease in type 1 diabetes
Date:11/12/2011

Controlling blood glucose early in the course of type 1 diabetes yields huge dividends, preserving kidney function for decades. The new finding from a study funded by the National Institutes of Health was published online in the New England Journal of Medicine Nov. 12 to coincide with presentation at a scientific meeting.

Compared to conventional therapy, near-normal control of blood glucose beginning soon after diagnosis of type 1 diabetes and continuing an average six and a half years reduced by half the long-term risk of developing kidney disease, according to the Diabetes Control and Complications Trial (DCCT) and Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. The risk of kidney failure was also halved, but the difference was not statistically significant, perhaps due to the relatively small total number of patients who reached that stage of the disease.

Participants entered the DCCT on average six years after onset of diabetes when complications of diabetes were absent or very mild. Half aimed for near-normal glucose control (intensive therapy) and the others received what was then standard glucose control. After an average 22-year follow-up, 24 in the intensive group developed significantly reduced kidney function and 8 progressed to kidney failure requiring dialysis or transplantation. On conventional therapy, 46 developed kidney disease, with kidney failure in 16.

The landmark DCCT demonstrated that intensive control reduced early signs of eye, kidney and nerve damage and is the basis for current guidelines for diabetes therapy. However, the initial kidney findings were based on reductions in urine protein, a sign of kidney damage but not a measure of kidney function. Preventing a loss of kidney function and reducing kidney failure had not been proven.

Since the DCCT ended in 1993, all participants have tried to maintain excellent diabetes control and have achieved similar glucose levels. The new finding emphasizes the importance of good control of type 1 diabetes soon after diagnosis.

"Achieving near-normal glucose levels in type 1 diabetes can be challenging. But our study provides strong evidence that reinforces the benefits of reaching the goal as early as possible to slow or prevent kidney disease and other complications," said first author Ian H. de Boer, M.D., a kidney specialist at the University of Washington, Seattle. He is scheduled to present the findings Nov. 12, 2011, at the American Society of Nephrology's annual meeting in Philadelphia.

The DCCT, conducted from 1983 to 1993 in 1,441 people with type 1 diabetes, found that intensive glucose control was superior to conventional control in delaying or preventing complications overall. EDIC continues to follow 1,375 DCCT participants to determine the long-term effects of the therapies beyond the initial treatment period. Other reports have bolstered support for intensive treatment to reduce the risk of heart disease, stroke and eye and nerve damage associated with diabetes.

"The DCCT and EDIC studies illustrate the value of long-term studies. The full benefit of treatment may not be seen for decades, especially for complications of diabetes, such as kidney disease, which can progress slowly but have devastating consequences," said Griffin P. Rodgers, M.D., director of the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which oversaw the research. "Not only has NIH-sponsored research shown the benefits of early glucose control, it has provided new tools to help people with type 1 diabetes achieve that control and live longer and healthier lives."

The DCCT compared intensive to conventional control of blood glucose in people with type 1 diabetes. At the time, conventional treatment was one or two insulin injections a day with daily urine or blood glucose testing. Participants randomly assigned to intensive treatment were asked to keep glucose levels as near normal as possible. That meant trying to keep hemoglobin A1c (A1C) readings at 6 percent or less with at least three insulin injections a day or an insulin pump, guided by frequent self-monitoring of blood glucose. (A1C reflects average blood glucose over the previous two to three months.)


'/>"/>
Contact: Mary M. Harris
niddkmedia@mail.nih.gov
301-435-8114
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Source:Eurekalert

Related medicine news :

1. Early, Intensive Therapy Better for Kids With Autism, Study Finds
2. Stroke prevention trial finds intensive medical treatment has better results than brain stenting
3. Caution Urged in Intensive Treatment of Type 2 Diabetes
4. Intensive care nurses have doubts about method for establishing brain death
5. Intensive, hands-on effort reduces bloodstream infections in critically ill patients
6. Nudging doctors in intensive care unit reduces deaths
7. Study in PLoS: Intensive adherence counseling to HIV treatment improves patient outcomes
8. Rep. Giffords Intensive Rehab Under Way
9. Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients
10. Once upon a time in the Intensive Care Unit ...
11. University Hospitals Case Medical Centers neuroscience intensive care unit earns Beacon Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: